P-1984. Assessing the clinical impact of the BioFire FilmArray Blood Culture Identification 2 (BCID2) Panel in the Selection of Effective Antibiotic Therapy at an Academic Medical Center

Abstract Background The BioFire FilmArray Blood Culture Identification (BCID2) panel uses polymerase chain reaction technology to rapidly identify pathogens and antimicrobial resistance genes in positive blood cultures. Using the BCID2 panel alongside an antimicrobial stewardship program has been proven to decrease time to effective targeted therapy. We aimed to evaluate the impact of the BCID2 panel in the management of bacteremia, focusing on the early administration of effective antibiotics. Methods Retrospective data was collected from adult patients with positive blood cultures at SUNY Downstate Health Sciences University between January 2021 to December 2024. The BCID2 panel was implemented in February 2022. The primary endpoint, of time between index positive blood culture and first dose of effective antibiotic, was assessed in participants before and after the implementation of the BCID2 panel. The secondary endpoints were time to appropriate antibiotic from index positive blood culture as defined by the institution’s BCID2 protocol, 30-day in-hospital mortality, and hospital length of stay. Results In total, 405 index positive blood cultures were sampled (n= 203 before the BCID2 panel implementation and n= 202 after). Baseline characteristics are presented in Table 1. The primary and secondary outcomes are summarized in Table 2 and 3, respectively. The median time between the index positive blood culture and first dose of effective antibiotic before and after BCID2 implementation was 1 vs. 2 hours, respectively (p= 0.916). For organisms with gram-negative resistance, the median time to effective antibiotics was 34 hours vs. 22 hours (p= 0.045). Conclusion The BCID2 panel was not associated with shorter time between index positive blood culture and first dose of effective or appropriate antibiotic. When analyzing blood cultures that contained organisms with gram-negative resistance, the BCID2 panel was associated with a shorter time to effective and appropriate antibiotics. Disclosures All Authors: No reported disclosures

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.2151
Primary Topic
Bacterial Identification and Susceptibility Testing
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-1984. Assessing the clinical impact of the BioFire FilmArray Blood Culture Identification 2 (BCID2) Panel in the Selection of Effective Antibiotic Therapy at an Academic Medical Center

Stanley Moy, Amar Dave
Open Forum Infectious Diseases
Bacterial Identification and Susceptibility Testing
article

P-1984. Assessing the clinical impact of the BioFire FilmArray Blood Culture Identification 2 (BCID2) Panel in the Selection of Effective Antibiotic Therapy at an Academic Medical Center

Stanley Moy, Amar Dave
article en

Abstract

Abstract Background The BioFire FilmArray Blood Culture Identification (BCID2) panel uses polymerase chain reaction technology to rapidly identify pathogens and antimicrobial resistance genes in positive blood cultures. Using the BCID2 panel alongside an antimicrobial stewardship program has been proven to decrease time to effective targeted therapy. We aimed to evaluate the impact of the BCID2 panel in the management of bacteremia, focusing on the early administration of effective antibiotics. Methods Retrospective data was collected from adult patients with positive blood cultures at SUNY Downstate Health Sciences University between January 2021 to December 2024. The BCID2 panel was implemented in February 2022. The primary endpoint, of time between index positive blood culture and first dose of effective antibiotic, was assessed in participants before and after the implementation of the BCID2 panel. The secondary endpoints were time to appropriate antibiotic from index positive blood culture as defined by the institution’s BCID2 protocol, 30-day in-hospital mortality, and hospital length of stay. Results In total, 405 index positive blood cultures were sampled (n= 203 before the BCID2 panel implementation and n= 202 after). Baseline characteristics are presented in Table 1. The primary and secondary outcomes are summarized in Table 2 and 3, respectively. The median time between the index positive blood culture and first dose of effective antibiotic before and after BCID2 implementation was 1 vs. 2 hours, respectively (p= 0.916). For organisms with gram-negative resistance, the median time to effective antibiotics was 34 hours vs. 22 hours (p= 0.045). Conclusion The BCID2 panel was not associated with shorter time between index positive blood culture and first dose of effective or appropriate antibiotic. When analyzing blood cultures that contained organisms with gram-negative resistance, the BCID2 panel was associated with a shorter time to effective and appropriate antibiotics. Disclosures All Authors: No reported disclosures

Open Forum Infectious DiseasesVol. 13(Supplement_1)
SUNY Downstate Health Sciences University (US)
Good health and well-being
Openalex Percentile: Top 87%
Bacterial Identification and Susceptibility Testing
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.